Particle.news
Download on the App Store

Daily Coffee Tied to Fewer AFib Recurrences in Randomized Trial

A JAMA study of post-cardioversion patients found fewer rhythm relapses with a daily cup of caffeinated coffee compared with abstinence.

Overview

  • The DECAF randomized trial assigned 200 habitual or recent coffee drinkers to drink at least one caffeinated cup daily or avoid caffeine for six months after cardioversion.
  • Coffee drinkers had a 39% lower risk of recurrent atrial fibrillation or atrial flutter, with recurrences detected through clinic ECGs and wearable monitoring at scheduled follow-ups.
  • Participants were enrolled across hospitals in the United States, Canada, and Australia, and outcomes were assessed at one, three, and six months.
  • Researchers noted limits including modest sample size, imperfect adherence in the avoidance group, and findings that reflect moderate intake rather than heavy consumption.
  • Experts said the results align with 2023 ACC/AHA guidance that caffeine abstention does not prevent AFib and urged individualized advice for patients considering caffeine use.